Oral Biologics & Biosimilars Market Growth Is Reshaping Competitive Advantage Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Oral Biologics & Biosimilars Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for oral biologics and biosimilars has seen exponential expansion over recent years, climbing from $9.37 billion in 2025 to $11.28 billion in 2026—a compound annual growth rate (CAGR) of 20.3%. During the historic period, this growth was driven by several factors including the scarce supply of oral biologic options, the steep price of biologic treatments, a continued preference for injectable forms, rising rates of chronic illnesses, and the expansion of both hospital and retail pharmacy networks.
Over the coming years, the oral biologics and biosimilars market is anticipated to experience explosive expansion. By 2030, its value is projected to hit $24.69 billion, fueled by a compound annual growth rate of 21.6%. This projected growth is primarily driven by the advancement of biosimilars and combination therapies, a broadening pipeline of oral biologics, a growing preference among patients for oral drug formats, increased use of digital tools to support medication adherence, and stronger financial backing and reimbursement frameworks from governments. Key trends shaping this period include the increasing application of oral biologics and biosimilars for managing chronic illnesses, a surge in targeted therapeutic approaches for conditions like diabetes, arthritis, and cancer, heightened development of oral treatments based on monoclonal antibodies, the widening reach of hospital, retail, and online pharmacy channels, and a sharper focus on ensuring patient compliance and developing tailored treatment regimens.
Download A Free Sample Report For Comprehensive Market Insights:
Oral Biologics & Biosimilars Market Opportunity Drivers: What Is Creating New Revenue Potential?
The increasing occurrence of long-term illnesses is anticipated to boost the expansion of the oral biologics and biosimilars market moving forward. Chronic diseases are persistent medical conditions that tend to advance slowly, including diabetes, heart disease, and respiratory ailments like asthma. This uptick in chronic conditions is mainly fueled by sedentary habits, as extended periods of physical inactivity elevate the likelihood of obesity, heart problems, type 2 diabetes, and some forms of cancer. Oral biologics and biosimilars facilitate this transition by offering more reachable, economically viable, and easier treatment options for individuals managing ongoing health issues. For example, in January 2023, the Centers for Disease Control and Prevention (CDC), a federal agency in the United States, reported that 76.4% of American adults—about 194 million people—had at least one chronic condition in 2023, with rates of 59.5% among young adults, 78.4% among middle-aged adults, and 93.0% among older adults. As a result, the growing prevalence of chronic diseases is fueling the growth of the oral biologics and biosimilars market.
Oral Biologics & Biosimilars Market Segment Landscape: Which Areas Lead Market Development?
The oral biologics & biosimilars market covered in this report is segmented –
1) By Therapy: Lymphocyte Modulators, Immunostimulants, GPCR Modulators, Other Therapies
2) By Disease: Diabetes, Arthritis and Crohn’s Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators
2) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants
3) By GPCR Modulators: Agonists, Antagonists, Biased Ligands
4) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies
Oral Biologics & Biosimilars Market Innovation Trends Driving Future Development
Key players in the oral biologics and biosimilars market are prioritizing the creation of advanced solutions, such as tailored smart capsule development services, to enhance the oral delivery of biologics, improve bioavailability, and provide a more patient-friendly alternative to conventional injectable formulations. These smart capsules incorporate sophisticated coatings, controlled-release matrices, or protective excipients that shield biologics from degradation within the gastrointestinal tract and facilitate absorption in specific intestinal regions, offering a non-invasive option that boosts patient adherence to treatment. For example, in December 2024, Lonza Group AG, a Swiss contract development and manufacturing organization (CDMO), unveiled a specialized service for smart capsule development, aimed at advancing oral biologics. This service includes personalized formulation design, careful selection of protective excipients, and capsule engineering to maintain biologic stability and targeted release; it operates by increasing the oral bioavailability of sensitive biomolecules while ensuring therapeutic effectiveness. Distinctive features encompass comprehensive support from concept through preclinical testing, adaptability to various biologic types (such as proteins, peptides, and nucleic acids), and scalable manufacturing options. Its applications extend to the oral delivery of monoclonal antibodies, therapeutic peptides, and vaccines. Benefits encompass enhanced patient convenience, decreased dependence on injections, better treatment compliance, and faster development timelines for oral biologic treatments.
Oral Biologics & Biosimilars Market Industry Leaders And Market Competition
Major companies operating in the oral biologics & biosimilars market are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme
Access The Complete Oral Biologics & Biosimilars Market Report:
Oral Biologics & Biosimilars Market Largest Region By Revenue And Market Share
North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
